Trial Profile

An EBV mRNA Vaccine (WGc-043 Injection) in Patients With EB Virus-positive Relapsed or Refractory Lymphoma: A Phase I Clinical Trial Assessing the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Anti-tumor Activity

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs WGc 043 (Primary)
Indications Diffuse large B cell lymphoma; Lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
Focus Therapeutic Use

28 Mar 2025 Planned initiation date changed from 10 Feb 2025 to 1 Apr 2025.
16 Sep 2024 According to a WestGene Biopharma media release, clinical data from this study presented as mini-oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024.
07 Aug 2024 According to a WestGene Biopharma media release, the company announce that WGc-043, has received dual IND approvals from China's National Medical Products Administration (NMPA) and the US FDA, allowing the initiation of this Phase I clinical trials.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com